Myomo (NYSE: MYO) is one of 33 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it weigh in compared to its peers? We will compare Myomo to similar companies based on the strength of its dividends, institutional ownership, earnings, analyst recommendations, profitability, valuation and risk.
This table compares Myomo and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Myomo and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Myomo||$3.84 million||-$10.71 million||-0.23|
|Myomo Competitors||$1.25 billion||$176.03 million||40.45|
Myomo’s peers have higher revenue and earnings than Myomo. Myomo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Myomo has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Myomo’s peers have a beta of 0.67, meaning that their average stock price is 33% less volatile than the S&P 500.
Institutional & Insider Ownership
4.2% of Myomo shares are held by institutional investors. Comparatively, 50.0% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 12.6% of Myomo shares are held by company insiders. Comparatively, 8.9% of shares of all “Surgical appliances & supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current ratings for Myomo and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Myomo presently has a consensus price target of $8.00, suggesting a potential upside of 78.17%. As a group, “Surgical appliances & supplies” companies have a potential downside of 2.16%. Given Myomo’s higher possible upside, research analysts plainly believe Myomo is more favorable than its peers.
Myomo peers beat Myomo on 10 of the 13 factors compared.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace orthosis product used for supporting a patient's weak or paralyzed arm to enable and enhance functional activities of daily living, ADLs, in the home and community. Its products are designed to help restore function in individuals with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, rehabilitation hospitals, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.